Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Jounce Therapeutics, Inc. JNCE
$1.88
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
98954740.00000000
-
week52high
5.37
-
week52low
0.58
-
Revenue
82000000
-
P/E TTM
0
-
Beta
0.75121100
-
EPS
-0.98000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Baird | Neutral | Outperform | 11 мая 2022 г. |
| Raymond James | Strong Buy | Outperform | 06 мая 2022 г. |
| SMBC Nikko | Outperform | 16 мар 2022 г. | |
| Raymond James | Strong Buy | Strong Buy | 31 авг 2022 г. |
| Raymond James | Outperform | Strong Buy | 11 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cole Hugh M | D | 110082 | 9182 | 10 янв 2023 г. |
| Drapkin Kimberlee C | D | 66018 | 7781 | 10 янв 2023 г. |
| MURRAY RICHARD /CA/ | D | 228007 | 24879 | 10 янв 2023 г. |
| Trehu Elizabeth | D | 103417 | 5126 | 10 янв 2023 г. |
| Cole Hugh M | D | 119264 | 7452 | 09 янв 2023 г. |
| Drapkin Kimberlee C | D | 73799 | 6315 | 09 янв 2023 г. |
| MURRAY RICHARD /CA/ | D | 252886 | 20191 | 09 янв 2023 г. |
| Trehu Elizabeth | D | 108543 | 4159 | 09 янв 2023 г. |
| Cole Hugh M | A | 40000 | 40000 | 01 авг 2022 г. |
| Cole Hugh M | A | 126716 | 20000 | 01 авг 2022 г. |
Новостная лента
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Zacks Investment Research
28 мар 2023 г. в 13:44
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.
Penny Stocks To Buy Now: 7 To Watch Before Next Week
PennyStocks
17 мар 2023 г. в 11:05
Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
Zacks Investment Research
16 мар 2023 г. в 13:00
Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.
5 Top Penny Stocks To Buy In March According To Insiders
PennyStocks
16 мар 2023 г. в 12:43
Insiders are buying these penny stocks but are they worth the risk? The post 5 Top Penny Stocks To Buy In March According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Navigating Volatile Penny Stocks: Essential Tips for Investors
PennyStocks
16 мар 2023 г. в 06:00
Use these tips for investing in volatile penny stocks The post Navigating Volatile Penny Stocks: Essential Tips for Investors appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.